{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:39:32Z","timestamp":1791092372304,"version":"4.1.0"},"reference-count":21,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6,1]]},"abstract":"<jats:p>Mineralocorticoids and glucocorticoids have been involved in the genesis of ventricular arrhythmias associated with pathological heart hypertrophy. We previously observed, using isolated neonate rat ventricular cardiomyocytes, that both aldosterone (Aldo) and corticosterone induced in vitro a marked acceleration of the spontaneous contractions of these cells, a phenomenon dependent on the expression of the low threshold T-type calcium channels. Because both mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) mediated the chronotropic response to corticosteroids, we characterized the role of each receptor using spironolactone and mifepristone (RU-486) as specific antagonists. We first observed that GR antagonism, but not MR antagonism, completely disrupted the significant correlation existing between the level of T channel mRNA and the beating frequency; this difference could not be explained by a specific regulation of channel expression or activity by one of the receptors. Moreover, the chronotropic action of Aldo was additive to that of forskolin, a direct activator of the cAMP pathway. This additive response was selectively abolished upon GR inhibition. Finally, myocyte hypertrophy induced in vitro by Aldo was completely prevented by GR antagonism, whereas spironolactone had only a marginal effect. These results suggest that, in isolated rat ventricular cardiomyocytes, the activation of both MR and GR is necessary for a complete electrical remodeling and a maximal chronotropic response to corticosteroids. However, GR alone appears involved in the sensitization of the cells to the chronotropic regulation through the cAMP pathway and in the hypertrophic response to steroids. These observations have therapeutic implications given the fact that MR becomes a major target of pharmacological drugs in the clinical practice for preventing cardiac function decompensation and evolution toward heart failure and lethal arrhythmias.<\/jats:p>","DOI":"10.1210\/en.2009-1375","type":"journal-article","created":{"date-parts":[[2010,4,15]],"date-time":"2010-04-15T01:34:10Z","timestamp":1271295250000},"page":"2777-2787","source":"Crossref","is-referenced-by-count":41,"title":["Contribution of Mineralocorticoid and Glucocorticoid Receptors to the Chronotropic and Hypertrophic Actions of Aldosterone in Neonatal Rat Ventricular Myocytes"],"prefix":"10.1210","volume":"151","author":[{"given":"Michel F.","family":"Rossier","sequence":"first","affiliation":[{"name":"Service of Endocrinology and Diabetology (M.F.R., M.P.) University Hospital of Geneva, CH-1211 Geneva 14, Switzerland;"},{"name":"Department of Internal Medicine, and Service of Laboratory Medicine (M.F.R.) University Hospital of Geneva, CH-1211 Geneva 14, Switzerland; Department of Genetics and Laboratory Medicine, University Hospital of Geneva, CH-1211 Geneva 14, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magaly","family":"Python","sequence":"first","affiliation":[{"name":"Service of Endocrinology and Diabetology (M.F.R., M.P.) University Hospital of Geneva, CH-1211 Geneva 14, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre\u0301s D.","family":"Maturana","sequence":"first","affiliation":[{"name":"Department of Bioengineering (A.D.M.), Nagaoka University of Technology, Niigata 940-2188, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2010,4,14]]},"reference":[{"key":"2020071613095008500_R1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00003495-200262050-00001","article-title":"Rationale for the use of aldosterone antagonists in congestive heart failure.","volume":"62","author":"Rocha","year":"2002","journal-title":"Drugs"},{"key":"2020071613095008500_R2","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","article-title":"Reconsidering the roles of the mineralocorticoid receptor.","volume":"53","author":"Funder","year":"2009","journal-title":"Hypertension"},{"key":"2020071613095008500_R3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"New Engl J Med"},{"key":"2020071613095008500_R4","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071613095008500_R5","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jama.297.14.1562","article-title":"Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial.","volume":"297","author":"Halonen","year":"2007","journal-title":"JAMA"},{"key":"2020071613095008500_R6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ajem.2006.12.007","article-title":"The effect of hydrocortisone on the outcome of out-of-hospital cardiac arrest patients: a pilot study.","volume":"25","author":"Tsai","year":"2007","journal-title":"Am J Emerg Med"},{"key":"2020071613095008500_R7","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure.","volume":"115","author":"Gu\u0308der","year":"2007","journal-title":"Circulation"},{"key":"2020071613095008500_R8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","article-title":"Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study.","volume":"90","author":"Souverein","year":"2004","journal-title":"Heart"},{"key":"2020071613095008500_R9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11906-007-0020-8","article-title":"Why are mineralocorticoid receptors so nonselective?","volume":"9","author":"Funder","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"2020071613095008500_R10","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1073\/pnas.80.19.6056","article-title":"Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity.","volume":"80","author":"Krozowski","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071613095008500_R11","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1681\/ASN.2004121110","article-title":"Mineralocorticoid versus glucocorticoid receptor occupancy mediating aldosterone-stimulated sodium transport in a novel renal cell line.","volume":"16","author":"Gaeggeler","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2020071613095008500_R12","first-page":"1","article-title":"Corticosteroid action on the heart: good guys or bad boys?","volume":"5","author":"Rossier","year":"2008","journal-title":"Curr Top Steroid Res"},{"key":"2020071613095008500_R13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cardiores.2005.05.009","article-title":"Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes.","volume":"67","author":"Laleve\u0301e","year":"2005","journal-title":"Cardiovasc Res"},{"key":"2020071613095008500_R14","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1210\/en.2008-1727","article-title":"Role of the T-type calcium channel CaV3.2 in the chronotropic action of corticosteroids in isolated rat ventricular myocytes.","volume":"150","author":"Maturana","year":"2009","journal-title":"Endocrinology"},{"key":"2020071613095008500_R15","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/HYPERTENSIONAHA.108.114223","article-title":"Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes.","volume":"52","author":"Rossier","year":"2008","journal-title":"Hypertension"},{"key":"2020071613095008500_R16","doi-asserted-by":"crossref","first-page":"H2540","DOI":"10.1152\/ajpheart.2000.279.5.H2540","article-title":"T-type calcium currents in rat cardiomyocytes during postnatal development: contribution to hormone secretion","volume":"279","author":"Leuranguer","year":"2000","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2020071613095008500_R17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-5793(93)80733-B","article-title":"Phosphorylation of the L-type calcium channel \u03b2 subunit is involved in \u03b2-adrenergic signal transduction in canine myocardium.","volume":"335","author":"Haase","year":"1993","journal-title":"FEBS Lett"},{"key":"2020071613095008500_R18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/0300-9084(95)80008-5","article-title":"cAMP-dependent phosphorylation of the cardiac L-type Ca channel: a missing link?","volume":"77","author":"Charnet","year":"1995","journal-title":"Biochimie"},{"key":"2020071613095008500_R19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cardiores.2006.09.001","article-title":"Ahnak, a new player in \u03b2-adrenergic regulation of the cardiac L-type Ca2+ channel.","volume":"73","author":"Haase","year":"2007","journal-title":"Cardiovasc Res"},{"key":"2020071613095008500_R20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/01.RES.0000204575.94040.d1","article-title":"High basal protein kinase A-dependent phosphorylation drives rhythmic internal Ca2+ store oscillations and spontaneous beating of cardiac pacemaker cells.","volume":"98","author":"Vinogradova","year":"2006","journal-title":"Circ Res"},{"key":"2020071613095008500_R21","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.HYP.0000203772.78696.67","article-title":"Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.","volume":"47","author":"Nagata","year":"2006","journal-title":"Hypertension"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/151\/6\/2777\/9012477\/endo2777.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/151\/6\/2777\/9012477\/endo2777.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T03:25:31Z","timestamp":1635218731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/151\/6\/2777\/2456878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,14]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2009-1375","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,14]]}}}